Inpatient outcomes of preterm infants receiving ω-3 enriched lipid emulsion (SMOFlipid): an observational study

Original Article

Abstract

Neonatal units have started to switch from using conventional soy-based to alternate lipid emulsions, like SMOFlipid. SMOFlipid has been associated with an improvement in biochemical parameters and delays progression of parenteral nutrition-associated liver disease (PNALD). This retrospective epoch study aimed to compare clinically relevant neonatal outcomes in preterm infants (< 32 weeks), receiving SMOFlipid versus Intralipid. We compared clinical outcomes in two epochs—epoch 1 (Intralipid, October 2013–June 2015) versus epoch 2 (SMOFlipid, July 2015–March 2017). Primary outcome studied was mortality and rates of severe neonatal morbidities. Univariate and multivariate regression was conducted to determine risk for mortality and PNALD. A total of 222 infants (epoch 1, 123 versus epoch 2, 99) were included in the study. A higher incidence of late onset sepsis (56 versus 30%, p < 0.005) was observed in epoch 1. There was no significant difference in mortality or rates of any other severe neonatal morbidity. The type of lipid emulsion did not have a significant effect on mortality or PNALD on regression analysis.

Conclusion: Use of SMOFlipid as the primary lipid emulsion seems to have minimal effect on rates of clinically important neonatal outcomes; however, long-term effects need to be further evaluated.

What is Known:

Many neonatal units have started replacing traditional soy-based lipid formulations with SMOFlipid (ω-3 enriched lipid emulsion), as the primary lipid component in parenteral nutrition for preterm infants.

While there is evidence associating improved liver function and balanced essential fatty acid levels in infants receiving SMOFlipid, there is a lack of evidence evaluating relevant clinical outcomes in infants receiving SMOFlipid versus traditional lipid formulations.

What is New:

The influence of SMOFlipid on a series of clinical outcomes in an at-risk preterm population is presented.

SMOFlipid appears to be well tolerated in preterm infants with minimal side effects, and some growth benefits seen.

Keywords

Parenteral nutrition Liver disease Intralipid Bronchopulmonary dysplasia 

Abbreviations

APH

Antepartum haemorrhage

ARA

Arachidonic acid

BPD

Bronchopulmonary dysplasia

CI

Confidence interval

DHA

Docosahexaenoic acid

EPA

Eicosapentaenoic acid

IQR

Interquartile range

IUGR

Intrauterine growth restriction

IVH

Intraventricular haemorrhage

LCPUFA

Long-chain polyunsaturated fatty acids

MCT

Medium chain triglycerides

NEC

Necrotising enterocolitis

NICU

Neonatal intensive care unit

OFC

Occipitofrontal circumference

OR

Odds ratio

PROM

Premature rupture of membranes

ROP

Retinopathy of prematurity

SD

Standard deviation

TPN

Total parenteral nutrition

Notes

Acknowledgements

The authors wish to thank Ms. Megan Williams, Pharmacist, Monash Health.

Authors’ Contributions

NC performed the data collection and analysis, wrote the first draft and approved the final version of the manuscript. KT assisted in data analysis, critically reviewed and approved the final version of the manuscript. AM formulated the research question, critically reviewed and approved the final version of the manuscript.

Compliance with ethical standards

Informed consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, Domellof M, Embleton ND, Fusch C, Genzel-Boroviczeny O, Goulet O, Kalhan SC, Kolacek S, Koletzko B, Lapillonne A, Mihatsch W, Moreno L, Neu J, Poindexter B, Puntis J, Putet G, Rigo J, Riskin A, Salle B, Sauer P, Shamir R, Szajewska H, Thureen P, Turck D, van Goudoever JB, Ziegler EE (2010) Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 50(1):85–91.  https://doi.org/10.1097/MPG.0b013e3181adaee0 CrossRefPubMedGoogle Scholar
  2. 2.
    Beken S, Dilli D, Fettah ND, Kabatas EU, Zenciroglu A, Okumus N (2014) The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial. Early Hum Dev 90(1):27–31.  https://doi.org/10.1016/j.earlhumdev.2013.11.002 CrossRefPubMedGoogle Scholar
  3. 3.
    Carlson SE, Werkman SH, Peeples JM, Cooke RJ, Tolley EA (1993) Arachidonic acid status correlates with first year growth in preterm infants. Proc Natl Acad Sci U S A 90(3):1073–1077CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Collins CT, Gibson RA, Makrides M, McPhee AJ, Sullivan TR, Davis PG, Thio M, Simmer K, Rajadurai VS (2016) The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks' gestation. BMC Pediatr 16:72.  https://doi.org/10.1186/s12887-016-0611-0 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    D'Ascenzo R, D'Egidio S, Angelini L, Bellagamba MP, Manna M, Pompilio A, Cogo PE, Carnielli VP (2011) Parenteral nutrition of preterm infants with a lipid emulsion containing 10% fish oil: effect on plasma lipids and long-chain polyunsaturated fatty acids. J Pediatr 159(1):33–38.e31.  https://doi.org/10.1016/j.jpeds.2010.12.052 CrossRefPubMedGoogle Scholar
  6. 6.
    Deshpande G, Simmer K, Deshmukh M, Mori TA, Croft KD, Kristensen J (2014) Fish Oil (SMOFlipid) and olive oil lipid (Clinoleic) in very preterm neonates. J Pediatr Gastroenterol Nutr 58(2):177–182.  https://doi.org/10.1097/mpg.0000000000000174 CrossRefPubMedGoogle Scholar
  7. 7.
    Diamond IR, Grant RC, Pencharz PB, de Silva N, Feldman BM, Fitzgerald P, Sigalet D, Dicken B, Turner J, Marchand V, Ling SC, Moore AM, Avitzur Y, Wales PW (2016) Preventing the progression of intestinal failure–associated liver disease in infants using a composite lipid emulsion: a pilot randomized controlled trial of SMOFlipid. J Parenter Enter Nutr 41(5):866–877.  https://doi.org/10.1177/0148607115626921 CrossRefGoogle Scholar
  8. 8.
    Fell GL, Nandivada P, Gura KM, Puder M (2015) Intravenous lipid emulsions in parenteral nutrition. Adv Nutr (Bethesda, Md) 6(5):600–610.  https://doi.org/10.3945/an.115.009084 CrossRefGoogle Scholar
  9. 9.
    Fusch C, Bauer K, Böhles HJ, Jochum F, Koletzko B, Krawinkel M, Krohn K, Mühlebach S, Working group for developing the guidelines for parenteral nutrition of The German Society for Nutritional M (2009) Neonatology/Paediatrics—Guidelines on Parenteral Nutrition, Chapter 13. GMS German Medical Science 7:Doc15. doi: https://doi.org/10.3205/000074
  10. 10.
    Guthrie G, Kulkarni M, Vlaardingerbroek H, Stoll B, Ng K, Martin C, Belmont J, Hadsell D, Heird W, Newgard CB, Olutoye O, van Goudoever J, Lauridsen C, He X, Schuchman EH, Burrin D (2016) Multi-omic profiles of hepatic metabolism in TPN-fed preterm pigs administered new generation lipid emulsions. J Lipid Res 57(9):1696–1711.  https://doi.org/10.1194/jlr.M069526 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hojsak I, Colomb V, Braegger C, Bronsky J, Campoy C, Domellof M, Embleton N, Fidler Mis N, Hulst JM, Indrio F, Lapillonne A, Mihatsch W, Molgaard C, van Goudoever J, Fewtrell M (2016) ESPGHAN Committee on Nutrition position paper. Intravenous lipid emulsions and risk of hepatotoxicity in infants and children: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr 62(5):776–792.  https://doi.org/10.1097/mpg.0000000000001121 CrossRefPubMedGoogle Scholar
  12. 12.
    Huffman SL, Harika RK, Eilander A, Osendarp SJM (2011) Essential fats: how do they affect growth and development of infants and young children in developing countries? A literature review. Matern Child Nutr 7(s3):44–65.  https://doi.org/10.1111/j.1740-8709.2011.00356.x CrossRefPubMedGoogle Scholar
  13. 13.
    Kapoor V, Glover R, Malviya MN (2015) Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants. Cochrane Database Syst Rev 12.  https://doi.org/10.1002/14651858.CD009172.pub2
  14. 14.
    Kelly DA (2010) Preventing parenteral nutrition liver disease. Early Hum Dev 86(11):683–687.  https://doi.org/10.1016/j.earlhumdev.2010.08.012 CrossRefPubMedGoogle Scholar
  15. 15.
    Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R (2005) 1. Guidelines on paediatric parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 41(Suppl 2):S1–87CrossRefPubMedGoogle Scholar
  16. 16.
    Lee EJ, Simmer K, Gibson RA (1993) Essential fatty acid deficiency in parenterally fed preterm infants. J Paediatr Child Health 29(1):51–55CrossRefPubMedGoogle Scholar
  17. 17.
    Mirtallo JM, Dasta JF, Kleinschmidt KC, Varon J (2010) State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann Pharmacother 44(4):688–700.  https://doi.org/10.1345/aph.1M626 CrossRefPubMedGoogle Scholar
  18. 18.
    Muhammed R, Bremner R, Protheroe S, Johnson T, Holden C, Murphy MS (2012) Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. J Pediatr Gastroenterol Nutr 54(6):797–802.  https://doi.org/10.1097/MPG.0b013e3182447daf CrossRefPubMedGoogle Scholar
  19. 19.
    Nandivada P, Carlson SJ, Chang MI, Cowan E, Gura KM, Puder M (2013) Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions. Adv Nutr (Bethesda, Md) 4(6):711–717.  https://doi.org/10.3945/an.113.004770 CrossRefGoogle Scholar
  20. 20.
    Pichler J, Simchowitz V, Macdonald S, Hill S (2014) Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure. Eur J Clin Nutr 68(10):1161–1167.  https://doi.org/10.1038/ejcn.2014.118 CrossRefPubMedGoogle Scholar
  21. 21.
    Rayyan M, Devlieger H, Jochum F, Allegaert K (2012) Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr 36(1 Suppl):81s–94s.  https://doi.org/10.1177/0148607111424411 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Savini S, D'Ascenzo R, Biagetti C, Serpentini G, Pompilio A, Bartoli A, Cogo PE, Carnielli VP (2013) The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving parenteral nutrition: a randomized clinical trial. Am J Clin Nutr 98(2):312–318.  https://doi.org/10.3945/ajcn.112.056556 CrossRefPubMedGoogle Scholar
  23. 23.
    Simopoulos AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21(6):495–505CrossRefPubMedGoogle Scholar
  24. 24.
    Su B-H (2014) Optimizing nutrition in preterm infants. Pediatr Neonatol 55(1):5–13.  https://doi.org/10.1016/j.pedneo.2013.07.003 CrossRefPubMedGoogle Scholar
  25. 25.
    Szajewska H, Horvath A, Koletzko B (2006) Effect of n-3 long-chain polyunsaturated fatty acid supplementation of women with low-risk pregnancies on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials. Am J Clin Nutr 83(6):1337–1344CrossRefPubMedGoogle Scholar
  26. 26.
    Taylor JE, McDonald SJ, Earnest A, Buttery J, Fusinato B, Hovenden S, Wallace A, Tan K (2017) A quality improvement initiative to reduce central line infection in neonates using checklists. Eur J Pediatr 176(5):639–646.  https://doi.org/10.1007/s00431-017-2888-x CrossRefPubMedGoogle Scholar
  27. 27.
    Uauy R, Hoffman DR (2000) Essential fat requirements of preterm infants. Am J Clin Nutr 71(1 Suppl):245s–250sPubMedGoogle Scholar
  28. 28.
    Uthaya S, Liu X, Babalis D, Dore CJ, Warwick J, Bell J, Thomas L, Ashby D, Durighel G, Ederies A, Yanez-Lopez M, Modi N (2016) Nutritional Evaluation and Optimisation in Neonates: a randomized, double-blind controlled trial of amino acid regimen and intravenous lipid composition in preterm parenteral nutrition. Am J Clin Nutr 103(6):1443–1452.  https://doi.org/10.3945/ajcn.115.125138 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Vlaardingerbroek H, Vermeulen MJ, Carnielli VP, Vaz FM, van den Akker CH, van Goudoever JB (2014) Growth and fatty acid profiles of VLBW infants receiving a multicomponent lipid emulsion from birth. J Pediatr Gastroenterol Nutr 58(4):417–427.  https://doi.org/10.1097/mpg.0000000000000280 CrossRefPubMedGoogle Scholar
  30. 30.
    Waitzberg DL, Torrinhas RS, Jacintho TM (2006) New parenteral lipid emulsions for clinical use. JPEN J Parenter Enteral Nutr 30(4):351–367CrossRefPubMedGoogle Scholar
  31. 31.
    Wanten GJ, Calder PC (2007) Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 85(5):1171–1184PubMedGoogle Scholar
  32. 32.
    Zhao Y, Wu Y, Pei J, Chen Z, Wang Q, Xiang B (2015) Safety and efficacy of parenteral fish oil-containing lipid emulsions in premature neonates. J Pediatr Gastroenterol Nutr 60(6):708–716.  https://doi.org/10.1097/mpg.0000000000000665 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Nalin Choudhary
    • 1
  • Kenneth Tan
    • 2
    • 3
    • 4
  • Atul Malhotra
    • 2
    • 3
    • 4
  1. 1.Monash UniversityMelbourneAustralia
  2. 2.Monash Newborn, Monash Children’s HospitalMelbourneAustralia
  3. 3.The Ritchie CentreHudson Institute of Medical ResearchMelbourneAustralia
  4. 4.Department of PaediatricsMonash UniversityMelbourneAustralia

Personalised recommendations